A Cardiac Liability Study of Varegacestat in Healthy Participants
← catalyst calendarSponsored by Immunome, Inc. (industry) · IMNM — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Other
Enrollment
32actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-24 | actual | When the study began enrolling |
| Primary completion | 2025-04-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-06 | actual | The whole study's end, after follow-up |
| First posted | 2025-03-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: varegacestat
- Drug: Placebo
- Drug: Moxifloxacin 400 mg
Primary outcome
what the primary-completion date above is the date OFPlacebo-corrected change from baseline QTc and varegacestat and its metabolite, AL102 MTB, plasma concentrations
measured 24 hours
Permalink · IMNM's whole pipeline · Catalyst calendar · Every registered study · What changed